Related Experiment Videos
[Intermediate-term trial treatment of arrhythmia in hypertrophic myocardiopathy with sotalol]
C Fournier1, C Bourmayan, M Cadillac
1Service de Cardiologie, Hôpital de Bicêtre, Le Kremlin-Bicêtre.
Insights
Sotalol, a beta-blocker, shows efficacy in treating heart rhythm disorders in hypertrophic cardiomyopathy patients. This study evaluated sotalol
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blockers are generally ineffective for severe ventricular rhythm disorders in hypertrophic cardiomyopathy.
- Amiodarone is effective but has potential side effects.
- Sotalol, a beta-blocker with antiarrhythmic properties, warrants investigation for hypertrophic cardiomyopathy rhythm issues.
Purpose of the Study:
- To evaluate the efficacy of sotalol in managing supraventricular and ventricular rhythm disorders in patients with hypertrophic cardiomyopathy.
Main Methods:
- A study involving 13 patients diagnosed with hypertrophic cardiomyopathy.
- 48-hour electrocardiographic recordings were taken before and at 8 and 120 days after sotalol treatment.
- Patients received a mean sotalol dose of 290 mg/day.
Main Results:
- A decrease in supraventricular tachycardia episodes was observed from 5 patients at baseline to 3 at 120 days.
- The number of patients with Lown's class III or IV ventricular rhythm disorders changed from 6 at baseline to 2 at 8 days and 4 at 120 days.
- Sotalol demonstrated a notable effect on rhythm disturbances in this patient group.
Conclusions:
- Sotalol exhibits non-negligible efficacy in treating supraventricular and ventricular rhythm disorders associated with hypertrophic cardiomyopathy.
- Further research with larger cohorts is recommended to confirm these findings.
Abstract:
Unlike amiodarone, beta-blockers have proved ineffective in the treatment of severe ventricular rhythm disorders encountered in hypertrophic myocardiopathy. We tried to evaluate the efficacy of sotalol, a betablocker with anti-arhythmic properties, like amiodarone, on the supraventricular and ventricular rhythm disorders of this disease. 13 patients (6 men and 7 women, mean age 53.5 +/- 26.5 years) were evaluated with a 48 hours electrocardiographic recording, before and 8 and 120 days after a sotalol treatment at a mean dose of 290 mg/day (160 to 640 mg). The diagnosis of hypertrophic myocardiopathy was established on standard clinical, phonomecanographic (13 cases), sonocardiographic (13 cases) and haemodynamic (9 cases) criteria. Five patients presented bursts of supraventricular tachycardia on DO. Their number decreased to 4 on D8 and to 3 to D120. Six patients presented Lown's class III or IV ventricular rhythm disorders on DO. Their number went from 2 on D8 to 4 on D120. Therefore, in this short series, sotalol has shown a non-negligible efficacy on the rhythm disorders encountered in hypertrophic myocardiopathy.